Shandong Weigao Group Medical Polymer Company Limited (Weigao Group) disclosed a share buyback executed on 29 May 2026 under its newly granted repurchase mandate.
• Transaction details – Volume: 360,000 H-shares repurchased on the Hong Kong Stock Exchange. – Price range: HKD 3.31–3.35 per share; volume-weighted average price approximately HKD 3.33. – Cash outlay: HKD 1.20 million. – All repurchased shares will be held as treasury shares; none were cancelled.
• Capital structure impact – Issued shares (excluding treasury) declined to 4.46465 billion from 4.46501 billion, a marginal reduction of 0.0081%. – Treasury shares increased to 57.69 million from 57.33 million. – Total issued share count remained unchanged at 4.52233 billion, as the repurchased shares are held in treasury.
• Repurchase mandate utilisation – Shareholders approved a mandate on 29 May 2026 allowing the company to buy back up to 446.46 million shares. – The latest transaction represents 0.08% of the authorised limit, leaving roughly 446.10 million shares available for further repurchase.
• Post-buyback restrictions – In line with Hong Kong listing rules, Weigao Group is restricted from issuing new shares or selling treasury shares until 29 June 2026.
The company confirmed that the repurchase complied with all applicable regulatory requirements and that funds for the transaction have been fully settled.
Comments